The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy.
Early breast cancer
Laboratory index
Neoadjuvant chemotherapy
Pathologic complete response
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 May 2024
27 May 2024
Historique:
received:
31
01
2024
accepted:
24
05
2024
medline:
28
5
2024
pubmed:
28
5
2024
entrez:
27
5
2024
Statut:
epublish
Résumé
Neoadjuvant chemotherapy (NACT) is the standard treatment for locally advanced, high-risk breast cancer. Pathological complete response (pCR) improves survival. Peripheral blood-derived indices reflecting systemic inflammation and nutritional status have long been used as predictive and prognostic markers in solid malignancies. This retrospective study investigates whether eight commonly used indices in patients receiving NACT affect pCR and survival. This study includes 624 locally advanced breast cancer patients who received NACT. The biomarker indices were calculated from peripheral blood samples taken two weeks before starting chemotherapy. The indices' optimal cut-off values were determined using ROC Curve analysis. During a median follow-up period of 42 months, recurrence was detected in 146 patients, and 75 patients died. pCR was observed in 166 patients (26.6%). In univariate analysis, NLR, PLR, SII, PNI, HALP, and HRR were statistically significantly associated (p = 0.00; p = 0.03; p = 0.03; p = 0.02; p = 0.00; p = 0.02 respectively), but in multivariate analysis, only NLR was significantly predictive for pCR(p = 0.04). In multivariate analysis, the HGB/RDW score significantly predicted DFS(p = 0.04). The PNI score was identified as a marker predicting survival for both OS and PFS (p = 0.01, p = 0.01, respectively). In conclusion, peripheral blood-derived indices have prognostic and predictive values on pCR and survival. However, further studies are needed to validate our findings.
Identifiants
pubmed: 38802494
doi: 10.1038/s41598-024-63096-7
pii: 10.1038/s41598-024-63096-7
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
12123Informations de copyright
© 2024. The Author(s).
Références
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
pubmed: 33538338
doi: 10.3322/caac.21660
Wilkinson, L. & Gathani, T. Understanding breast cancer as a global health concern. Br. J. Radiol. 95(1130), 20211033 (2022).
pubmed: 34905391
doi: 10.1259/bjr.20211033
Waks, A. G. & Winer, E. P. Breast cancer treatment: A review. JAMA 321(3), 288–300. https://doi.org/10.1001/jama.2018.19323 (2019).
doi: 10.1001/jama.2018.19323
pubmed: 30667505
Tabor, S., Szostakowska-Rodzos, M., Fabisiewicz, A. & Grzybowska, E. A. How to predict metastasis in luminal breast cancer? Current solutions and future prospects. Int. J. Mol. Sci. 21(21), 8415 (2020).
pubmed: 33182512
pmcid: 7665153
doi: 10.3390/ijms21218415
Kerr, A. J. et al. Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality. Cancer Treat Rev. 105, 102375 (2022).
pubmed: 35367784
doi: 10.1016/j.ctrv.2022.102375
Spring, L. M. et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: A comprehensive meta-analysis. Clin. Cancer Res. 26(12), 2838–2848 (2020).
pubmed: 32046998
pmcid: 7299787
doi: 10.1158/1078-0432.CCR-19-3492
Dupré, A. & Malik, H. Z. Inflammation and cancer: What a surgical oncologist should know. Eur. J. Surg. Oncol. 44(5), 566–570. https://doi.org/10.1016/j.ejso.2018.02.209 (2018).
doi: 10.1016/j.ejso.2018.02.209
pubmed: 29530345
Şahin, A. B. et al. Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy. Sci. Rep. 11(1), 14662 (2021).
pubmed: 34282214
pmcid: 8289916
doi: 10.1038/s41598-021-94184-7
Hanahan, D. Hallmarks of cancer: New dimensions. Cancer Discov. 12(1), 31–46. https://doi.org/10.1158/2159-8290.CD-21-1059 (2022).
doi: 10.1158/2159-8290.CD-21-1059
pubmed: 35022204
Ugel, S., Canè, S., De Sanctis, F. & Bronte, V. Monocytes in the tumor microenvironment. Ann. Rev. Pathol. 24(16), 93–122. https://doi.org/10.1146/annurev-pathmechdis-012418-013058 (2021).
doi: 10.1146/annurev-pathmechdis-012418-013058
Kim, J. & Bae, J. S. Tumor-associated macrophages and neutrophils in tumor microenvironment. Med. Inflamm. 2016, 6058147 (2016).
doi: 10.1155/2016/6058147
Huong, P. T., Nguyen, L. T., Nguyen, X. B., Lee, S. K. & Bach, D. H. The role of platelets in the tumor-microenvironment and the drug resistance of cancer cells. Cancers (Basel) 11(2), 240 (2019).
pubmed: 30791448
doi: 10.3390/cancers11020240
Azab, B. et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med. Oncol. 30(1), 432 (2013).
pubmed: 23283648
doi: 10.1007/s12032-012-0432-4
Madeddu, C. et al. Pathogenesis and treatment options of cancer related anemia: Perspective for a targeted mechanism-based approach. Front. Physiol. 20(9), 1294 (2018).
doi: 10.3389/fphys.2018.01294
Rodgers, G. M. 3rd. et al. Cancer- and chemotherapy-induced anemia. J. Natl. Compr. Cancer Netw. 10(5), 628–653 (2012).
doi: 10.6004/jnccn.2012.0064
Obermair, A. et al. The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: A prospective review. Cancer 83(4), 726–731 (1998).
pubmed: 9708937
doi: 10.1002/(SICI)1097-0142(19980815)83:4<726::AID-CNCR14>3.0.CO;2-U
Zhang, Y. et al. Impact of preoperative anemia on relapse and survival in breast cancer patients. BMC Cancer 18(14), 844 (2014).
doi: 10.1186/1471-2407-14-844
An, M. S. et al. T4 stage and preoperative anemia as prognostic factors for the patients with colon cancer treated with adjuvant FOLFOX chemotherapy. World J. Surg. Oncol. 13, 64 (2015).
pubmed: 25889520
pmcid: 4336700
doi: 10.1186/s12957-015-0488-7
Seretis, C., Seretis, F., Lagoudianakis, E., Gemenetzis, G. & Salemis, N. S. Is red cell distribution width a novel biomarker of breast cancer activity? Data from a pilot study. J. Clin. Med. Res. 5(2), 121–126 (2013).
pubmed: 23518817
pmcid: 3601498
Ichinose, J. et al. Prognostic significance of red cell distribution width in elderly patients undergoing resection for non-small cell lung cancer. J. Thorac. Dis. 8(12), 3658–3666 (2016).
pubmed: 28149561
pmcid: 5227271
doi: 10.21037/jtd.2016.12.44
Eckart, A. et al. Relationship of nutritional status, inflammation, and serum albumin levels during acute illness: A prospective study. Am. J. Med. 133(6), 713-722.e7 (2020).
pubmed: 31751531
doi: 10.1016/j.amjmed.2019.10.031
Espinosa, E. et al. Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer 12(1–2), 67–76 (1995).
pubmed: 7600032
doi: 10.1016/0169-5002(95)00407-R
Ma, J. Y., Liu, G., Pan, L. Z., Hu, M. & Zhu, Z. Z. Clinical impact of pretreatment albumin-globulin ratio in patients with colorectal cancer: A meta-analysis. Medicine (Baltimore) 101(20), e29190 (2022).
pubmed: 35608420
doi: 10.1097/MD.0000000000029190
Oñate-Ocaña, L. F. et al. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann. Surg. Oncol. 14(2), 381–389. https://doi.org/10.1245/s10434-006-9093-x (2007).
doi: 10.1245/s10434-006-9093-x
pubmed: 17160496
Chen, L. et al. Prognostic nutritional index (PNI) in patients with breast cancer treated with neoadjuvant chemotherapy as a useful prognostic indicator. Front. Cell Dev. Biol. 30(9), 656741 (2021).
doi: 10.3389/fcell.2021.656741
Farag, C. M., Antar, R., Akosman, S., Ng, M. & Whalen, M. J. Addendum: What is hemoglobin, albumin, lymphocyte, platelet (HALP) score? A comprehensive literature review of HALP’s prognostic ability in different cancer types. Oncotarget 7(14), 748 (2023).
doi: 10.18632/oncotarget.28485
Yuce, E. et al. The effect of the change in hemoglobin-albumin-lymphocyte-platelet scores occurring with neoadjuvant chemotherapy on clinical and pathological responses in breast cancer. Bratisl. Lek. Listy. 124(1), 59–63 (2023).
pubmed: 36519609
Lou, C., Jin, F., Zhao, Q. & Qi, H. Correlation of serum NLR, PLR and HALP with efficacy of neoadjuvant chemotherapy and prognosis of triple-negative breast cancer. Am. J. Transl. Res. 14(5), 3240–3246 (2022).
pubmed: 35702128
pmcid: 9185079
Truffi, M. et al. Prognostic potential of immune inflammatory biomarkers in breast cancer patients treated with neoadjuvant chemotherapy. Cancers (Basel) 14(21), 5287 (2022).
pubmed: 36358706
doi: 10.3390/cancers14215287
Gasparri, M. L. et al. Low neutrophil-to-lymphocyte ratio and pan-immune-inflammation-value predict nodal pathologic complete response in 1274 breast cancer patients treated with neoadjuvant chemotherapy: A multicenter analysis. Ther. Adv. Med. Oncol. 15(15), 17588359231193732 (2023).
pubmed: 37720495
pmcid: 10504832
doi: 10.1177/17588359231193732
Büyükşimşek, M., Oğul, A., Mirili, C. & Paydaş, S. Inflammatory markers predicting pathological complete response in cases with breast cancer treated by neoadjuvant chemotherapy. Eur. J. Breast Health 16(4), 229–234 (2020).
pubmed: 33062961
pmcid: 7535993
doi: 10.5152/ejbh.2020.5556
Gu, Q., Zhao, J., Liu, Y., Chen, H. & Wang, L. Association between the systemic immune-inflammation index and the efficacy of neoadjuvant chemotherapy, prognosis in HER2 positive breast cancer-a retrospective cohort study. Gland Surg. 12(5), 609–618 (2023).
pubmed: 37284715
pmcid: 10240428
doi: 10.21037/gs-23-55
Yılmaz, A., Mirili, C., Tekin, S. B. & Bilici, M. The ratio of hemoglobin to red cell distribution width predicts survival in patients with gastric cancer treated by neoadjuvant FLOT: A retrospective study. Ir. J. Med. Sci. 189(1), 91–102 (2020).
pubmed: 31832860
doi: 10.1007/s11845-019-02153-x
Bozkaya, Y., Dilber, M., Bilgili, A. M. & Aktaş, C. A New prognostic parameter associated with recurrence in patients with nasopharyngeal cancer treated with chemoradiotherapy: The ratio of the hemoglobin-to-red cell distribution width. Cureus 15(6), e39907 (2023).
pubmed: 37404429
pmcid: 10317079
Eren, T. et al. Correlation between peripheral blood inflammatory indicators and pathologic complete response to neoadjuvant chemotherapy in locally advanced breast cancer patients. Medicine (Baltimore) 99(22), e20346 (2020).
pubmed: 32481414
doi: 10.1097/MD.0000000000020346
Hu, Y. et al. Platelet/lymphocyte ratio is superior to neutrophil/lymphocyte ratio as a predictor of chemotherapy response and disease-free survival in luminal B-like (HER2-) breast cancer. Clin. Breast Cancer 20(4), e403–e409 (2020).
pubmed: 32201163
doi: 10.1016/j.clbc.2020.01.008
Ma, Y., Zhang, J. & Chen, X. Lymphocyte-to-monocyte ratio is associated with the poor prognosis of breast cancer patients receiving neoadjuvant chemotherapy. Cancer Manag. Res. 16(13), 1571–1580 (2021).
doi: 10.2147/CMAR.S292048
Zhou, Y. et al. Predictive significance of systemic immune-inflammation index in patients with breast cancer: A retrospective cohort study. Onco Targets Ther. 16(16), 939–960 (2023).
pubmed: 38021447
pmcid: 10658965
Wang, C. et al. Two hematological markers predicting the efficacy and prognosis of neoadjuvant chemotherapy using lobaplatin against triple-negative breast cancer. Oncologist 29(5), e635–e642 (2024).
pubmed: 38431781
pmcid: 11067820
doi: 10.1093/oncolo/oyae025
Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell. 140(6), 883–899. https://doi.org/10.1016/j.cell.2010.01.025 (2010).
doi: 10.1016/j.cell.2010.01.025
pubmed: 20303878
pmcid: 2866629
Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420(6917), 860–867. https://doi.org/10.1038/nature01322 (2002).
doi: 10.1038/nature01322
pubmed: 12490959
pmcid: 2803035
Crusz, S. M. & Balkwill, F. R. Inflammation and cancer: Advances and new agents. Nat. Rev. Clin. Oncol. 12(10), 584–596 (2015).
pubmed: 26122183
doi: 10.1038/nrclinonc.2015.105
Zhou, Q. et al. Role of neutrophil-to-lymphocyte ratio as a prognostic biomarker in patients with breast cancer receiving neoadjuvant chemotherapy: A meta-analysis. BMJ Open. 11(9), e047957 (2021).
pubmed: 34561257
pmcid: 8475153
doi: 10.1136/bmjopen-2020-047957
Ishizuka, M., Nagata, H., Takagi, K., Iwasaki, Y. & Kubota, K. Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer. Br. J. Cancer. 109(2), 401–407 (2013).
pubmed: 23820256
pmcid: 3721384
doi: 10.1038/bjc.2013.350
Serhan, C. N. The resolution of inflammation: The devil in the flask and in the details. FASEB J. 25(5), 1441–1448 (2011).
pubmed: 21532053
pmcid: 3228345
doi: 10.1096/fj.11-0502ufm
Gajewski, T. F., Schreiber, H. & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14(10), 1014–1022 (2013).
pubmed: 24048123
pmcid: 4118725
doi: 10.1038/ni.2703
Guthrie, G. J. et al. The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer. Crit. Rev. Oncol. Hematol. 88(1), 218–230 (2013).
pubmed: 23602134
doi: 10.1016/j.critrevonc.2013.03.010
Cullinane, C. et al. Can the neutrophil to lymphocyte ratio predict complete pathologic response to neoadjuvant breast cancer treatment? A systematic review and meta-analysis. Clin. Breast Cancer 20(6), e675–e681 (2020).
pubmed: 32653471
doi: 10.1016/j.clbc.2020.05.008
Xue, L. B. et al. Prognostic role of high neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy: Meta-analysis. Medicine (Baltimore). 98(1), e13842 (2019).
pubmed: 30608401
pmcid: 6344113
doi: 10.1097/MD.0000000000013842
Feeney, G. et al. Association of clinical biomarkers and response to neoadjuvant therapy in breast cancer. Ir. J. Med. Sci. 193(2), 605–613 (2024).
pubmed: 37673801
doi: 10.1007/s11845-023-03489-1
Mantovani, A. Cancer: Inflammation by remote control. Nature 435(7043), 752–753 (2005).
pubmed: 15944689
doi: 10.1038/435752a
Mantzorou, M., Koutelidakis, A., Theocharis, S. & Giaginis, C. Clinical value of nutritional status in cancer: What is its impact and how it affects disease progression and prognosis?. Nutr. Cancer 69(8), 1151–1176 (2017).
pubmed: 29083236
doi: 10.1080/01635581.2017.1367947
Muscaritoli, M. et al. ESPEN practical guideline: Clinical nutrition in cancer. Clin. Nutr. 40(5), 2898–2913 (2021).
pubmed: 33946039
doi: 10.1016/j.clnu.2021.02.005
Qu, F. et al. Construction and validation of a prognostic nutritional index-based nomogram for predicting pathological complete response in breast cancer: A two-center study of 1,170 patients. Front. Immunol. 11(14), 1335546 (2024).
doi: 10.3389/fimmu.2023.1335546
Yang, G., Liu, P., Zheng, L. & Zeng, J. Novel peripheral blood parameters as predictors of neoadjuvant chemotherapy response in breast cancer. Front. Surg. 4(9), 1004687 (2022).
doi: 10.3389/fsurg.2022.1004687
Oba, T. et al. Neoadjuvant chemotherapy-induced decrease of prognostic nutrition index predicts poor prognosis in patients with breast cancer. BMC Cancer 20(1), 160 (2020).
pubmed: 32106833
pmcid: 7045374
doi: 10.1186/s12885-020-6647-4